In a February 6, 2018, decision, a Federal Circuit panel
reasoned that a pharmaceutical distribution agreement can qualify
as an invalidating “offer for sale” under 35 USC
section 102(b) when the terms of the agreement demonstrate the
commercial character and elements of an offer to sell a patented
product.
Background
The Medicines Company (Medicines) asserted two patents covering
its Angiomax anti-blood-clot drug product (the Product) against
Hospira, a generic drugmaker and Abbreviated New Drug Application
(ANDA) filer. Medicines developed a new method of formulating
Angiomax that reduced impurities. That formulation was the subject
of the asserted patents, which were filed on July 27, 2008. Prior
to that filing, Medicines, on February 27, 2007, entered into an
agreement with Integrated Commercialization Solutions, Inc. (ICS)
to distribute the Angiomax formulation. The agreement stated that
Medicines “desire[d] to sell the Product” to ICS and
that ICS “desire[d]